Hartmut Schneider



Hartmut Schneider is a US and German-qualified lawyer who practices antitrust law primarily before US agencies and courts. He has extensive experience in securing merger clearance for transactions in a diverse range of industries. He also regularly counsels clients on legal issues at the intersection of antitrust and intellectual property law, as well as on the compliance of joint ventures, other horizontal cooperation agreements and vertical distribution agreements with the antitrust laws.

Before relocating to Washington in 2005, Mr. Schneider worked in the Antitrust and Competition Department of the firm's Brussels and Berlin offices, as well as in the New York office. In addition to his US antitrust law expertise, Mr. Schneider has significant experience in EC and German competition law.

Honors & Awards

  • Selected as a top-rated antitrust litigation lawyer in 2016 and 2017 by Washington DC Super Lawyers
  • Recognized in the 2015, 2016 and 2017 editions of Global Competition Review's Who's Who Legal, The International Who's Who of Competition Lawyers and Economists
  • Recognized for antitrust in The Legal 500 (United States) (2012-2017) 
  • Listed in the 2014 edition of Expert Guides as a leading economist in Washington DC in the area of Competition/Antitrust Law

Publications & News


May 10, 2018

WilmerHale Counsels Braintree Laboratories in Acquisition by Sebela Pharmaceuticals

On May 1, 2018, Sebela Pharmaceuticals completed the acquisition of Braintree Laboratories Inc., a privately held specialty pharmaceutical company based in Braintree, Massachusetts. Braintree develops, manufactures and markets specialty pharmaceuticals in gastroenterology.

May 3, 2018

WilmerHale Lawyers and Practices Recognized in 2018 Edition of Chambers USA

Chambers and Partners announced its rankings for the 2018 edition of Chambers USA: America's Leading Lawyers for Business, with WilmerHale listed among the nation's best in 50 practice area categories. Chambers also ranked 95 WilmerHale lawyers as leaders in their respective fields.

March 26, 2018

Pre-Merger Information Sharing: The FTC Weighs In

A month ago, we covered recent European competition law developments on pre-merger information sharing and “gun jumping” among merging parties. In a timely reminder that the same questions also are relevant in the United States, the Federal Trade Commission recently issued a blog post on antitrust pitfalls during pre-merger discussions and due diligence.

February 16, 2018

Federal Trade Commission Update: Senate Hearings Reveal No Obvious Hurdles For Commissioner Nominees

The Senate Commerce Committee held a hearing on Wednesday on the nominees to serve on the Federal Trade Commission. The hearing covered a range of antitrust and consumer protection issues before, or potentially before, the Commission, including healthcare competition and pharmaceutical pricing; competition in technology and telecommunications sectors; industry concentration; cybersecurity breaches and privacy; and online or telemarketing deception and scams.

February 14, 2018

Senior EU Court Adviser Provides Welcome Guidance on Gun-Jumping

EU and US laws prohibit merging companies from implementing reportable transactions until their deal is cleared or the statutory waiting period has expired.

January 29, 2018

HSR Size of Transaction Threshold to Increase to $84.4 Million

The Federal Trade Commission ("FTC") announced revised thresholds for merger notifications under the Hart-Scott-Rodino ("HSR") Act.

October 2, 2017

Wait, I Thought We Were Done? DOJ Challenges $4B Merger Months After HSR Filing and Expiration of the HSR Waiting Period

Earlier this week, the Antitrust Division of the Department of Justice filed a lawsuit seeking to unwind Parker-Hannifin's $4.3 billion consummated acquisition of Clarcor.

September 11, 2017

Eine Leitfigur lässt auf sich warten

In this editorial, published in the September 2017 issue of Neue Zeitschrift für Kartellrecht, Hartmut Schneider discusses the implications of the new administration for antitrust enforcement in the United States (in German).

August 3, 2017

Firm's Representation of Hilton is Honored as Global Finance Deal of the Year by The American Lawyer

For the past five years, The American Lawyer has hosted the Global Legal Awards to honor matters that demonstrate the industry's ability to navigate complex international legal issues.

July 24, 2017

WilmerHale Reps Emergent BioSolutions in $96M Acquisition of GlaxoSmithKline Anthrax Drug

Emergent BioSolutions announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million.

Recent Highlights

  • Advising Baker Hughes in connection with the global merger review of the proposed $32 billion combination with GE Oil & Gas, and previously with regard to Halliburton's proposed $34.6 billion acquisition of Baker Hughes.
  • Advising International Paper Company in obtaining clearance in the United States and seven other jurisdictions for its $2.2 billion acquisition of the pulp assets of Weyerhauser.
  • Assisting American Science & Engineering in securing antitrust clearance for its $269 million sale to OSI Systems.
  • Assisting Demandware in securing antitrust clearance for its $2.8 billion sale to
  • Assisting MKS Instruments in securing antitrust clearance for its $980 million acquisition of Newport Corporation.
  • Assisting leading academic publisher Springer Science+Business Media (SSBM) in securing merger control clearance in the United States, the European Commission and several other jurisdictions for the combination of SSBM with the majority of Holtzbrinck-owned Macmillan Science and Education (namely Nature Publishing Group, Palgrave Macmillan and the global businesses of Macmillan Education) in a joint venture with approximately EUR 1.5 billion in annual revenues.
  • Assisting Analog Devices in securing antitrust clearance for its $2.5 billion acquisition of Hittite Microwave.
  • Advising Ophthotech Corporation in connection with a licensing and commercialization agreement with Novartis Pharmaceuticals focused on the treatment of wet age-related macular degeneration.
  • Assisting International Paper Company in securing antitrust clearance for its $4.4B acquisition of Temple-Inland, Inc., and for the $710 million sale of its Temple-Inland Building Products division to Georgia-Pacific.
  • Defending Cephalon in "reverse payment" Hatch Waxman patent settlement cases pending in the Eastern District of Pennsylvania, including those brought by the Federal Trade Commission, Apotex, and a number of purported purchaser classes.
  • Advising the founders of a patent pool for Blu-ray optical media technology on US antitrust aspects of the pool's formation, and assisting in obtaining worldwide antitrust clearances for the establishment of the pool's licensing agent.

Professional Activities

Mr. Schneider currently serves as a member of the 2018 MLex Advisory Board, and is a co-chair of the ABA Section of Antitrust Law's Intellectual Property Committee. Previously, he served as co-chair of the ABA Spring Meeting (2013-2015), as a member of the Section's Long Range Planning and Nominating Committees, and as the assistant to the chair of the Section.


Skip Navigation Links.


LLM, University of Michigan Law School, 2000

Second State Exam, Berlin, Court of Appeals, 1999

Doctorate in Law, University of Freiburg, 1997

First State Exam, University of Freiburg, 1996

Licence en droit, University of Paris X - Nanterre, 1993

Bar Admissions

District of Columbia





Skip Navigation Links.